We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Astralis has announced that the Phase II study of its novel immunostimulatory
product for the treatment of psoriasis did not meet the primary study endpoint
upon completion of the treatment phase of the study.
Neurobiological Technologies has reported on an End of Phase II meeting with
the FDA regarding Viprinex, a product in clinical development for the treatment
of acute ischemic stroke.
Axonyx has reported additional detailed information from its first Phase III
clinical trial with Phenserine, in development for mild-to-moderate Alzheimer's
disease (AD).
Pharmacyclics has announced that patient enrollment has been completed in its
pivotal Phase III clinical trial of Xcytrin (motexafin gadolinium) injection
for the potential treatment of lung cancer patients with brain metastases.
The U.S. Patent and Trademark Office has awarded a patent to Genaissance Pharmaceuticals
for a method testing individuals for genetic predisposition to reduced metabolism
of drugs.
Adherex Technologies has announced that the Drug Development Group of the National
Cancer Institute's (NCI) Division of Cancer Treatment and Diagnosis has approved
a Level III collaboration for the clinical development of the company's lead
biotechnology compound ADH-1, also known as Exherin, provided additional preclinical
studies be conducted.
ViroPharma has announced results from the Phase Ib proof-of-concept study with
HCV-086, an orally dosed hepatitis C (HCV) inhibitor, being co-developed with
Wyeth.
Patients with Parkinson's disease (PD), who were optimized on levodopa therapy
and other PD therapies, experienced a significant reduction in the duration
of "off" time, as well as an improvement in motor symptom control
during both "on" and "off" periods when once-daily Agilect
was added to their treatment regimens.
Prana Biotechnology has commenced the Phase I clinical trial of PBT2 with the
dosing of its first subject at a facility associated with the Utrecht University
Hospital in Utrecht, Netherlands.